Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ejhf.2626 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pannexin channels in inflammation and tumorigenesis.
Front Cell Dev Biol
August 2025
Center for Pancreatic Cancer Research, The South China University of Technology School of Medicine, Guangzhou, China.
Pannexin (Panx) channels are oligomeric heptamers of PANX proteins, comprising Panx1, Panx2 and Panx3. These channels facilitate the extracellular release of signaling molecules up to 1.5 kDa in size, including adenosine triphosphate (ATP), amino acids, ions, and other metabolites.
View Article and Find Full Text PDFResolution of ventricular dysfunction and fibrosis in a young woman with primary hyperaldosteronism.
Hipertens Riesgo Vasc
August 2025
Diabetes and Cardiometabolism Department, Instituto Cardiovascular de Buenos Aires, Argentina.
A 25-year-old female was admitted to hospital due to a hypertensive crisis, presenting with ventricular dysfunction and renal impairment. Initial evaluations revealed a left ventricular ejection fraction of 46% with baseline inferolateral intramyocardial enhancement and a creatinine clearance of 45mL/min/1.73m, with proteinuria.
View Article and Find Full Text PDFEffect of spironolactone on monocyte subsets in atrial fibrillation: IMPRESS-AF randomised controlled trial.
Sci Rep
July 2025
Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool, UK.
Background: Monocyte subsets differentially influence pathophysiology of heart failure and atrial fibrillation (AF) through inflammation, fibrosis, and angiogenesis. Spironolactone has antifibrotic properties. This study investigated the effect spironolactone on monocyte subsets and monocyte effects for peak oxygen consumption (peakVO2), diastolic function and brain natriuretic peptide (BNP) in the IMPRESS-AF randomised controlled trial population (2-year treatment with spironolactone 25 mg vs placebo).
View Article and Find Full Text PDFUse of Spironolactone for the Treatment of Heart Failure With Preserved Ejection Fraction: Efficacy and Clinical Implications in Light of Recent Evidence.
Cureus
June 2025
Surgical Oncology, Tata Medical Centre, Kolkata, IND.
Heart failure with preserved ejection fraction (HFpEF) is a common condition that affects around half of individuals with heart failure (HF), which is associated with significant morbidity, mortality, and reduced quality of life. Even though there is a high prevalence, no pharmacological treatments have been proven to reduce mortality in HFpEF. Spironolactone has shown promise in improving diastolic function and decreasing ventricular stiffness in HFpEF patients.
View Article and Find Full Text PDFMineralocorticoid receptor activation contributes to intestinal fibrosis through neutrophil gelatinase-associated lipocalin in preclinical models.
Nat Commun
July 2025
Univ Rouen Normandie, INSERM, Normandie Univ, ADEN UMR 1073 Nutrition, Inflammation and Microbiota-Gut-Brain Axis, F-76000, Rouen, France.
Intestinal fibrosis is a common complication in inflammatory bowel diseases with no specific therapy. Because mineralocorticoid receptor antagonism prevented inflammation and fibrosis in extra-intestinal organs, we aimed to evaluate mineralocorticoid receptor antagonism in intestinal fibrosis. Here we show that pharmacological or smooth cell specific deletion mineralocorticoid receptor antagonism prevented colon fibrosis development in male mice.
View Article and Find Full Text PDF